Vera Therapeutics, Inc. (VERA)

Market Cap	599.84M
Revenue (ttm)	n/a
Net Income (ttm)	-102.77M
Shares Out	44.43M
EPS (ttm)	-2.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	271,782
Open	13.63
Previous Close	13.50
Day's Range	13.46 - 14.07
52-Week Range	5.20 - 21.02
Beta	0.83
Analysts	Buy
Price Target	20.33 (+46.79%)
Earnings Date	Nov 9, 2023

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA

Analyst Forecast

According to 6 analysts, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $20.33, which is an increase of 46.79% from the latest price.

Price Target

$20.33

(46.79% upside)

Analyst Consensus: Buy